Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

about

Biologics in pediatric psoriasis - efficacy and safety.Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4+ CD25high Foxp3+ regulatory T-cells in psoriasis.

P2860

Q42696430-9FB3036A-9EA2-4018-AAE8-07250154AD75 Q50349522-F599C917-9146-467C-8587-C28B4A6970FB

P2860

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

Item

http://www.wikidata.org/entity/Q26741357

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@ast

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@en

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@nl

type

Item

label

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@ast

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@en

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@nl

prefLabel

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@ast

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@en

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@nl

P1476

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

@en

P2093

Monica Mattes

http://www.w3.org/2001/XMLSchema#string

Sami K Saikaly

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-TNF agents for paediatric psoriasis

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

[Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].

Childhood psoriasis.

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.

Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation.

Management of psoriasis in adolescence.

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.

Pediatric psoriasis: updates in biologic therapies.

P304

e652

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1310480

http://www.w3.org/2001/XMLSchema#string

P356

10.7759/CUREUS.652

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27462478

http://www.w3.org/2001/XMLSchema#string

P932

4959817

http://www.w3.org/2001/XMLSchema#string

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

about

P2860

P2860

Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P577

P698

P932

P3181

P356

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P577

P698

P932